Review Papers Against Their Own Results

Topline critique

The review argues that epigenetic clocks (especially pediatric clocks such as PedBE and gestational clocks) are promising diagnostic biomarkers for childhood asthma and allergic disease but require more pediatric training data, tissue‑specific validation, and careful causal inference before clinical use Review Abstract and Scope

Quick actionable points

• Use pediatric-trained clocks (eg PedBE) for children; adult clocks can misestimate ages in pediatric samples PedBE performance excerpt
• Account for tissue and cell composition (IEAA versus EEAA) when associating EAA with asthma IEAA EEAA definitions

Comprehensive paper review and critique

1) What the paper does (accurate excerpted summary)

The authors review epigenetic clocks, explain metrics of epigenetic age acceleration and clock classes (first/second generation, pediatric and gestational clocks), summarize evidence linking epigenetic age acceleration to asthma and allergic disease across the life course, and identify limitations and research needs for pediatric biomarker development and validation Review Abstract and Scope

2) Major strengths

• Comprehensive taxonomy of clocks: first generation (Horvath pan-tissue, Hannum), second generation (PhenoAge, GrimAge), pediatric (PedBE), and gestational clocks with concrete performance numbers and tissue notes Clock taxonomy excerpt
• Focus on practical biomarker implementation issues: tissue accessibility (blood/saliva/buccal), CpG panel size, pediatric vs adult training, and clinical marker inclusion limits for second-generation clocks Second generation caution
• Connects epigenetic clock concept to asthma life course and DOHaD (developmental origins) framing, which is directly relevant to pediatric asthma risk prediction and diagnostics DOHaD and prenatal exposures

3) Key limitations and blindspots (critical analysis)

1. Adult‑trained clocks applied to children — The review itself stresses this limitation: most prominent clocks were trained on adult samples and can mis-estimate pediatric ages, limiting interpretability for childhood asthma studies; the PedBE clock is explicitly highlighted as an improved pediatric tool but is tissue‑specific (buccal) and performs worse in blood PedBE tissue specificity and limitation
2. Tissue and cell composition confounding — methylation is cell‑type specific; the review correctly emphasizes IEAA versus EEAA but stops short of operational guidance on how to deconvolute immune cell fractions in pediatric blood and airway samples or how to harmonize nasal epithelium clocks with blood-based measures IEAA EEAA caution
3. Causality vs correlation — the review correctly illustrates reverse causation/mediator scenarios (Figure 1) but, as a literature review, cannot resolve whether EAA causes asthma, is a mediator, or is a consequence; rigorous causal approaches (Mendelian randomization, longitudinal repeated measures with mediation models) are needed to test predictive biomarker claims Causality diagram excerpt
4. Population and ancestry gaps — the review notes cohorts such as Project Viva and Costa Rica (GACRS) but does not systematically address cross‑ancestry clock calibration or portability—essential for biomarkers intended for broad clinical use Empirical cohort examples
5. Clinical deployment challenges for second-generation clocks — PhenoAge/GrimAge include clinical biomarkers (eg albumin, creatinine, proteins) which improves mortality prediction but reduces ease of implementation in pediatric settings where these measures may be unavailable or uninformative Second generation implementation tradeoffs

4) Evidence linking epigenetic age acceleration to asthma and lung function

The review synthesizes studies showing positive associations between epigenetic age acceleration and pediatric asthma/allergy (Project Viva, GACRS, adolescent nasal epithelium study) and negative associations between EAA and FEV1/FEV1:FVC in adults and middle-aged cohorts EAA asthma associations

These associations are consistent but limited in sample size and design heterogeneity; the review correctly calls for more pediatric longitudinal data and mechanistic studies to move beyond association.

5) Reproducibility and data transparency

This is a narrative literature review; it collates published results but does not provide new primary data or a public analysis pipeline. The paper states data availability is not applicable for the review, which reduces direct reproducibility of any aggregate analyses; by contrast, reproducible meta-analyses require making extracted tables and code available Data availability statement

6) Practical recommendations for researchers (derived from the reviewed evidence)

• Use pediatric‑trained clocks for children and validate clocks in the target tissue (eg buccal PedBE for buccal samples; do not apply adult blood clocks to nasal epithelium without recalibration) PedBE tissue caution
• Explicitly control for cell composition or use IEAA metrics when comparing blood-based EAA across disease groups IEAA usage guidance
• Design longitudinal birth cohort analyses with repeated methylation measures (cord blood, early childhood, puberty) to test whether childhood EAA trajectories predict later asthma, and complement with causal methods (eg MR, sibling designs) to distinguish cause/consequence Need for longitudinal pediatric data

7) Visualization of clock performance across representative clocks

8) Conclusion: balanced take

The review is a careful, well‑referenced synthesis that credibly presents epigenetic clocks as a potentially useful diagnostic biomarker platform for asthma and allergic disease, especially if pediatric‑focused clocks and longitudinal validation are developed. However, the current evidence remains largely associative, tissue and training‑sample dependent, and insufficient to justify clinical deployment without further replication, causal testing, and cross‑ancestry validation Authors concluding caveat

9) Next steps and what would falsify the main claims

High quality falsification experiments: large multi-ancestry longitudinal pediatric cohorts showing no prospective association between childhood EAA trajectories and later asthma onset, or MR analyses demonstrating no causal path from genetically instrumented EAA to asthma, would undermine the claim that EAA predicts asthma risk (i.e., predictive biomarker status). Conversely, replication of prospective prediction and causal MR evidence would strengthen the claim.

Author reviews